Italia markets open in 1 hour 40 minutes

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
39.047,99
-21,69(-0,06%)
EUR/USD
1,0862
+0,0001(+0,01%)
Bitcoin EUR
65.287,41
+3.475,18(+5,62%)
CMC Crypto 200
1.523,70
+169,28(+12,50%)

NBIX May 2024 150.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

8,40

0,00

(0,00%)

In data: 01:56PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat